4/A: Verona Pharma Director Vikas Sinha Corrects Form 4 Filing, Reports Transactions in Ordinary Shares

Director Vikas Sinha amends a previous Form 4 filing to accurately reflect transactions in Verona Pharma's ordinary shares rather than American Depositary Shares (ADSs).

Summary

• Vikas Sinha, a director of Verona Pharma plc, filed an amended Form 4 with the SEC to correct a previous filing on May 1, 2025.
• The amendment clarifies that the reported transactions involved ordinary shares, not American Depositary Shares (ADSs).
• The transactions occurred on April 29, 2025, and included the acquisition and disposition of ordinary shares through option exercises and sales.
• Specifically, 120,384 ordinary shares were acquired at $1.7 and disposed of at $8.9208, and 39,616 ordinary shares were acquired at $0.5038 and disposed of at $8.9208.
• The sales were executed under a Rule 10b5-1 plan adopted on November 6, 2024, to cover the exercise price of the options.
• Following the reported transactions, Sinha directly owns 74,440 ordinary shares represented by 9,305 ADSs and holds options for 160,384 ordinary shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't inherently convey positive or negative sentiment, but the correction ensures accurate information is available to investors.

Industry Context

Form 4 filings are standard disclosures required by the SEC for company insiders, providing transparency into their trading activities. This filing is an amendment to correct a previous error, which is not uncommon.

Stakeholder Impact

• Shareholders benefit from accurate and transparent reporting of insider transactions.

Key Dates

Keywords

Verona Pharma, Form 4, Vikas Sinha, Ordinary Shares, ADS, SEC Filing, Director, Rule 10b5-1, Amendment, Transactions